BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
Express Scripts
Baxter
Chinese Patent Office
Daiichi Sankyo
Healthtrust
Deloitte
Medtronic
Argus Health

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,367,333

« Back to Dashboard

Which drugs does patent 7,367,333 protect, and when does it expire?

Patent 7,367,333 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in twenty-four countries.
Summary for Patent: 7,367,333
Title:Inhalation device
Abstract:Actuator for an inhaler for delivering medicament by inhalation. The actuator includes a main body having a tubular member for receiving a canister containing medicament and having a valve stem extending therefrom, and an outlet assembly, as a part formed separately of the main body, having a mouthpiece for guiding medicament to the mouth of a user and a nozzle block for receiving the valve stem of the canister and delivering medicament from the canister into the mouthpiece. At least a part of the outlet assembly is configured so as to deform and optionally break on withdrawal of the outlet assembly from the main body so as to prevent re-use of the outlet assembly.
Inventor(s): Hodson; Darren (Shropshire, GB), Rasmussen; Jorgen (Struer, DK)
Assignee: AstraZene a AB (Sodertalje, SE)
Application Number:10/698,950
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 7,367,333

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,367,333

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9704185Nov 14, 1997

Non-Orange Book US Patents Family Members for Patent 7,367,333

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,805,116 Inhalation device ➤ Subscribe
7,743,765 Inhalation device ➤ Subscribe
7,967,011 Inhalation device ➤ Subscribe
8,584,668 Inhalation device ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,367,333

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 66820 ➤ Subscribe
Taiwan 490308 ➤ Subscribe
Turkey 200001357 ➤ Subscribe
Slovakia 286209 ➤ Subscribe
Slovakia 7002000 ➤ Subscribe
Sweden 9704185 ➤ Subscribe
Russian Federation 2198688 ➤ Subscribe
Poland 191305 ➤ Subscribe
Poland 340493 ➤ Subscribe
New Zealand 504275 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
UBS
Queensland Health
Julphar
US Department of Justice
Baxter
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot